Repligen and Eli Lilly have agreed to renew their biotechnology and genetic engineering licensing agreement and extend it through 1996. The project was launched in 1992 and is focusing on the development of monoclonal antibodies directed against the CD11b receptor on neutrophils.
The extended agreement provides for the commercial manufacture by Lilly of the products developed by the collaboration, while Repligen will receive various payments relating to the transfer of rights and development milestones. The company will also receive increased royalties on net sales, compared to the original agreement.
Both companies have developed preclinical models which show that blocking the CD11b receptor with a compound designated as 60.1 can reduce the undesired inflammatory response seen in some medical conditions, including stroke and coronary artery bypass surgery. The drug is now in the Phase I/II development stage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze